Background/Aim: The adipocytokines leptin and adiponectin represent a critical link between metabolism, immunity and chronic inflammation. A chronic vascular inflammatory state plays an important role in the pathophysiology of thalassaemia. We aimed to analyze the levels of these adipocytokines and determine any possible correlations with disease severity or vascular inflammation markers in beta-thalassaemia. Methods: Serum leptin, adiponectin, high-sensitivity C-reactive protein, endothelins, vascular adhesion molecule-1, intracellular adhesion molecule-1 and L- and E-selectin were measured in 28 beta-thalassaemia patients and compared with levels in healthy controls. Results: Leptin was significantly lower in patients compared to controls (2.23 ± 1.8 vs. 10.24 ± 5.78 µg/l; p = 0.0018), whereas adiponectin was elevated (11.75 ± 5.67 vs. 6.83 ± 2.75 µg/l; p = 0.009). For both adipocytokines, no correlations were found with characteristics such as age, gender, type of chelation, body mass index z score or haemoglobin. Leptin, but not adiponectin, was negatively correlated with ferritin (p = 0.032, r = –0.61). No correlations were found between leptin and the inflammation markers. However, adiponectin was positively correlated with endothelin-1 (p = 0.022, r = 0.63). Conclusions: Serum leptin is low in beta-thalassaemia, perhaps due to the toxic effect of iron overload on adipose tissue. Paradoxically, adiponectin levels are high and positively correlated with endothelin-1, raising questions about the pro- or anti-inflammatory role of this adipocytokine in beta-thalassaemia.

Keywords:
Adiponectin, Inflammation, Iron overload, Leptin, Thalassaemia
1.
Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006;64:355–365.
2.
Bernotiene E, Palmer G, Gabay C: The role of leptin in innate and adaptive immune responses. Arthritis Res Ther 2006;8:217.
3.
Palmer G, Gabay C: A role for leptin in rheumatic diseases? Ann Rheum Dis 2003;62:913–915.
4.
Sun Y, Xun K, Wang C, Zhao H, Bi H, Chen X, Wang Y: Adiponectin, an unlocking adipocytokine. Cardiovasc Ther 2009;27:59–75.
5.
Ouchi N, Walsh K: Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380:24–30.
6.
Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, Paul G, Distler J, Gay S, Scholmerich J, Neumann E, Muller-Ladner U: The potential of adiponectin in driving arthritis. J Immunol 2006;176:4468–4478.
7.
Fayad R, Pini M, Sennello JA, Cabay RJ, Chan L, Xu A, Fantuzzi G: Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 2007;132:601–614.
8.
Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN: Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 2005;335:1254–1263.
9.
Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198–1201.
10.
Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, Makino H: Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545–1552.
11.
Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, Ito T, Nezu R, Tsutsui S, Miyagawa JI, Tamura S, Matsuzawa Y, Shimomura I, Shinomura Y: Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn’s disease. Gut 2005;54:789–796.
12.
Kanavaki I, Makrythanasis P, Lazaropoulou C, Tsironi M, Kattamis A, Rombos I, Papassotiriou I: Soluble endothelial adhesion molecules and inflammation markers in patients with beta-thalassemia intermedia. Blood Cells Mol Dis 2009;43:230–234.
13.
Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G: Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol 1999;106:178–181.
14.
Cappellini MD: Coagulation in the pathophysiology of hemolytic anemias. Hematology Am Soc Hematol Educ Program 2007;74–78.
15.
Aggeli C, Antoniades C, Cosma C, Chrysohoou C, Tousoulis D, Ladis V, Karageorga M, Pitsavos C, Stefanadis C: Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int J Cardiol 2005;105:80–84.
16.
Chiotis D, Krikos X, Tsiftis G, Hatzisymeon M, Maniati-Christidi M, Dacou-Voutetaki A: Body mass index and prevalence of obesity in subjects of Hellenic origin aged 0–18 years living in the Athens area. Ann Clin Pediatr Univ Atheniensis 2004;51:139–154.
17.
Dedoussis GV, Kyrtsonis MC, Andrikopoulos NE, Voskaridou E, Loutradis A: Inverse correlation of plasma leptin and soluble transferrin receptor levels in beta-thalassemia patients. Ann Hematol 2002;81:543–547.
18.
Moshtaghi-Kashanian GR, Razavi F: Ghrelin and leptin levels in relation to puberty and reproductive function in patients with beta-thalassemia. Hormones (Athens) 2009;8:207–213.
19.
Karachaliou F, Vlachopapadopoulou E, Theochari M, Konstandellou E, Michalados S: Leptin levels in patients with thalassemia major. Minerva Pediatr 2006;58:373–378.
20.
Perrone L, Perrotta S, Raimondo P, Mucerino J, De Rosa C, Siciliani MC, Santoro N, Miraglia del Giudice E: Inappropriate leptin secretion in thalassemia: a potential cofactor of pubertal timing derangement. J Pediatr Endocrinol Metab 2003;16:877–881.
21.
Miraglia Del Giudice E, Perrotta S, Carbone MT, Calabro C, Esposito L, De Rosa C, Saviano A, Di Toro R, Perrone L: Evaluation of leptin protein levels in patients with Cooley’s anaemia. Br J Haematol 1999;105:839–840.
22.
Youson JH, Sargent PA: Iron deposition in the integument of lampreys. Anat Rec 1984;209:461–468.
23.
Rejholcova M, Wilhelm J, Svoboda P: Lipid peroxidation inhibits norepinephrine-stimulated lipolysis in rat adipocytes. Reduction of beta-adreno-ceptor number. Biochem Biophys Res Commun 1988;150:802–810.
24.
Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE: Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004;35:842–849.
25.
Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM: Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004;145:5589–5597.
26.
Juan CC, Chuang TY, Chang CL, Huang SW, Ho LT: Endothelin-1 regulates adiponectin gene expression and secretion in 3T3-L1 adipocytes via distinct signaling pathways. Endocrinology 2007;148:1835–1842.
27.
Fantuzzi G: Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008;121:326–330.
28.
Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E: Thalassemia. Hematology Am Soc Hematol Educ Program 2004;14–34.
29.
Kattamis C, Kattamis AC: Oxidative stress disturbances in erythrocytes of beta-thalassemia. Pediatr Hematol Oncol 2001;18:85–88.
30.
Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P: Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006;135:254–263.
31.
Behre CJ: Adiponectin: saving the starved and the overfed. Med Hypotheses 2007;69:1290–1292.
32.
Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T, Suzuki R, Satoh H, Tsuchida A, Moroi M, Sugi K, Noda T, Ebinuma H, Ueta Y, Kondo T, Araki E, Ezaki O, Nagai R, Tobe K, Terauchi Y, Ueki K, Minokoshi Y, Kadowaki T: Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007;6:55–68.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.